AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
4.18 USD -3.69% Intraday chart for AbCellera Biologics Inc. -6.90% -26.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions CI
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 CI
AbCellera Biologics Inc. Announces Board Changes CI
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $9 MT
Stifel Lowers Price Target on AbCellera Biologics to $17 From $21, Maintains Buy Rating MT
Transcript : AbCellera Biologics Inc., 2023 Earnings Call, Feb 20, 2024
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Reports Fiscal 2023 Revenue $38M MT
Transcript : AbCellera Biologics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
KeyBanc Initiates AbCellera Biologics at Overweight With $6 Price Target, Cites 'Robust' Platform, 'Attractive' Valuation MT
Abcellera Biologics, Inc. Announces Reorganization CI
AbCellera Biologics, Inc. Announces Reduction in Workforce CI
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 CI
Transcript : AbCellera Biologics Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q3 Revenue $6.6M, vs. Street Est of $11.5M MT
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target MT
AbCellera Expands Antibody Discovery Collaboration With Regeneron MT
AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery Collaboration with Regeneron CI
AbCellera Biologics Shares Rise After COO Stock Purchases Disclosed MT
AbCellera and Incyte to Collaborate on Therapeutic Antibody Development in Oncology MT
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology CI
Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating MT
Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating MT
Chart AbCellera Biologics Inc.
More charts
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.18 USD
Average target price
14.75 USD
Spread / Average Target
+252.87%
Consensus
  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. News AbCellera Biologics Inc.
  5. AbCellera Biologics : Swings to Q2 Loss; Revenue Rises